Sutro Biopharma reports 2025 revenue of $102.5 million, net loss of $191.1 million
Sutro Biopharma reported full-year 2025 results in a press release furnished with an 8-K on March 23, 2026. Revenue rose to $102.5 million from $62.0 million and net loss narrowed to $191.1 million from $227.5 million, but the company also recorded $53.4 million in restructuring and related costs. The company also terminated its at-the-market share sales agreement with Jefferies LLC effective March 23, 2026, so it can no longer sell common shares under that program.
- Revenue was $102.5 million for 2025, up from $62.0 million in 2024, mainly tied to Astellas and Ipsen collaborations.
- Net loss was $191.1 million, or $22.49 per share, versus $227.5 million, or $29.40 per share, in 2024.
- Restructuring and related costs were $53.4 million in 2025, compared with none in 2024.
- Cash, cash equivalents and marketable securities were $141.4 million at December 31, 2025, versus $316.9 million a year earlier.